![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein Following Sorafenib: Outcomes by Liver Disease Aetiology from Two Randomised, Placebo-Controlled Phase 3 Studies
(REACH-2 And REACH)
|
|
|
Reported by Jules Levin
EASL 2019 April 10-14 Vienna
![0417191](../images/041819/041819-8/0417191.gif)
![0417192](../images/041819/041819-8/0417192.gif)
![0417193](../images/041819/041819-8/0417193.gif)
![0417194](../images/041819/041819-8/0417194.gif)
![0417195](../images/041819/041819-8/0417195.gif)
![0417196](../images/041819/041819-8/0417196.gif)
![0417197](../images/041819/041819-8/0417197.gif)
![0417198](../images/041819/041819-8/0417198.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|